Title |
Adjuvant therapy with minocycline for schizophrenia (The MINOS Trial): study protocol for a double-blind randomized placebo-controlled trial
|
---|---|
Published in |
Trials, November 2013
|
DOI | 10.1186/1745-6215-14-406 |
Pubmed ID | |
Authors |
Abebaw Fekadu, Miraf Mesfin, Girmay Medhin, Atalay Alem, Solomon Teferra, Tsehaysina Gebre-Eyesus, Teshale Seboxa, Abraham Assefa, Jemal Hussein, Martha T Lemma, Christina Borba, David C Henderson, Charlotte Hanlon, Teshome Shibre |
Abstract |
Schizophrenia is understood to be a heterogeneous brain condition with overlapping symptom dimensions. The negative symptom dimension, with its protean cognitive manifestations, responds poorly to treatment, which can be a particular challenge in countries where clozapine therapy is not available. Preliminary data indicate that minocycline may be beneficial adjunct in the treatment of schizophrenia: positive, negative, and cognitive symptoms.In this study we aim to assess the efficacy of adjunctive minocycline to alleviate symptoms of schizophrenia in patients who have failed to respond to a therapeutic trial of antipsychotic medications. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Chile | 1 | 1% |
Unknown | 85 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 12 | 14% |
Researcher | 10 | 12% |
Student > Bachelor | 9 | 10% |
Student > Doctoral Student | 8 | 9% |
Other | 7 | 8% |
Other | 18 | 21% |
Unknown | 22 | 26% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 25 | 29% |
Psychology | 11 | 13% |
Nursing and Health Professions | 6 | 7% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 5% |
Biochemistry, Genetics and Molecular Biology | 2 | 2% |
Other | 7 | 8% |
Unknown | 31 | 36% |